

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/007,628	11/08/2001		Fergal Conan Hill	674508-2008 9992		
20999	7590	10/03/2003		EXAMINER		
FROMME 745 FIFTH		ENCE & HAUG	HILL, MYRON G			
	EW YORK, NY 10151			ART UNIT	PAPER NUMBER	
				1648	$\alpha$	
				DATE MAILED: 10/03/2003	, 9	
					/	

Please find below and/or attached an Office communication concerning this application or proceeding.

<del>, '-</del> ,		Application No.	Applicant(s)	
		10,7007,628	HILL ET AL.	
	Office Action Summary	Examiner	Art Unit	
		Myron G. Hill	1648	
Period f	The MAILING DATE of this communication app	ears on the cover sheet v	vith the correspondence addr s	SS
A SH THE - Exte afte	HORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION.  The ensions of time may be available under the provisions of 37 CFR 1.13  TO SIX (6) MONTHS from the mailing date of this communication.  The eperiod for reply specified above is less than thirty (30) days, a reply	36(a). In no event, however, may a	reply be timely filed	
- If No - Faili - Any earn	O period for reply is specified above, the maximum statutory period wave to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	vill apply and will expire SIX (6) MC, cause the application to become A	NTHS from the mailing date of this commu BANDONED (35 U.S.C. § 133).	inication.
Status				
1)	Responsive to communication(s) filed on			
2a)□	,—	is action is non-final.		
3) Disposit	Since this application is in condition for allowal closed in accordance with the practice under a tion of Claims			erits is
· ·	Claim(s) 1- 36 is/are pending in the application	٦.		
/_	4a) Of the above claim(s) is/are withdraw			
5)□	Claim(s) is/are allowed.			
	Claim(s) is/are rejected.			
7)	Claim(s) is/are objected to.			
	Claim(s) 1- 36 are subject to restriction and/or	election requirement.		
	ion Papers			
9)	The specification is objected to by the Examiner	г.		
10)	The drawing(s) filed on is/are: a) accep	oted or b)  objected to by	the Examiner.	
	Applicant may not request that any objection to the	e drawing(s) be held in abe	rance. See 37 CFR 1.85(a).	
11)	The proposed drawing correction filed on	is: a)□ approved b)□	disapproved by the Examiner.	
	If approved, corrected drawings are required in rep	ly to this Office action.		
12)	The oath or declaration is objected to by the Exa	aminer.		
Priority (	under 35 U.S.C. §§ 119 and 120			
13)	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C.	§ 119(a)-(d) or (f).	
a)	☐ All b)☐ Some * c)☐ None of:			
	1. Certified copies of the priority documents	s have been received.		
	2. Certified copies of the priority documents	s have been received in a	Application No	
* (	3. Copies of the certified copies of the prior application from the International Bur See the attached detailed Office action for a list of the control of the control of the certified of the certified of the certified of the certified copies of the prior of the certified copies of th	eau (PCT Rule 17.2(a)).		је
	Acknowledgment is made of a claim for domestic	·		alication)
•	a)  The translation of the foreign language pro	•	•	mounting.
	Acknowledgment is made of a claim for domestic	• •		
Attachmen	nt(s)			
2) 🔲 Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152	



Application/Control Number: 10/007,628

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 2, 5, 7, 9, drawn to a polypeptide monomer comprising T4 Gp31 with heterologous amino acid(s) inserted, classified in class 530, subclass 300.
- II. Claims 2, 6, 8, 10, drawn to a polypeptide monomer comprising E coli Gro ES with heterologous amino acid(s) inserted, classified in class 530, subclass 300.
- III. Claims 2, 11, drawn to a polypeptide comprising a scaffold with a heterologous sequence at the C or N terminal positions, classified in class 530, subclass 300.
- IV. Claim 22, 28, drawn to use of a polypeptide for detection, classified in class 435, subclass 4.
- IV. Claim 22, 28, drawn to use of a polypeptide for neutralization, classified in class 424, subclass 184.1.
- V. Claims 35, 36, drawn to a nucleic acid sequence, classified in class 536, subclass 23.4.

Claims 1, 3, and 4 are linking claims.

Claim 2 is generic and included in all groups.

Application/Control Number: 10/007,628

Art Unit: 1648

Claims 10- 21, 23- 27, 29- 34 will be examined with the elected invention as they read on the elected invention.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to different structures, either different polypeptide backbones or different locations of heterologous sequence.

Inventions IV and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are different methods of use, one requires detection only and the other requires the polypeptide be able to neutralize an activity which requires a different function as well as different result from the method.

Inventions I, II, III and IV, V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the methods can be practiced with the other different inventive polypeptides.

Inventions VI and I, II, III are related as process of making and product made.

The inventions are distinct if either or both of the following can be shown: (1) that the





Art Unit: 1648

process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the polypeptides can be made by a peptide synthesizer machine.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, different structures and methods, restriction for examination purposes as indicated is proper.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. See inventive groups listed above. Currently, 1, 3, 4 are linking/generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Myron G. Hill whose telephone number is 703-308-4521. The examiner can normally be reached on 9am-6pm Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4247. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

MI

Myron G. Hill Patent Examiner October 1, 2003

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600